Transitioning CLL FISH analysis into the molecular biomarker era

Dr. Tucker shares her experience of how OGT’s NGS panel, SureSeq™ CLL + CNV, has streamlined her laboratory workflow and enabled the detection of various aberrations in key genes implicated in CLL progression, including SNVs, indels, and CNVs. This alleviates the burden of running multiple assays and delivers comprehensive results with a single NGS analysis.
Disclaimer: This presentation is intended for educational purposes only and does not replace independent professional judgment. Statements of fact and opinions expressed are those of the presenters individually and, unless expressly stated to the contrary, are not the opinion or position of the Oxford Gene Technology Group (OGT). OGT does not endorse or approve, and assumes no responsibility for, the content, accuracy or completeness of the information presented.